Tag: FDA approval
-
![Revive Therapeutics (RVV.C) incredible patent-portfolio explained]()
Revive Therapeutics (RVV.C) incredible patent-portfolio explained
Revive Therapeutics (RVV.C) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. RVV holds 13 patents (issued and provisional) for covid-treatment, gout, drug delivery systems, cannabidiol and psilocybin. “We are proud of the IP portfolio that we’ve generated,” stated Michael Frank, CEO of Revive…
-
![Revive Therapeutics (RVV.C) latest spate of Bucillamine research could slow COVID-19 infection rates]()
Revive Therapeutics (RVV.C) latest spate of Bucillamine research could slow COVID-19 infection rates
Revive Therapeutics (RVV.C) signed a research agreement with the University of California, San Francisco (UCSF) to explore Bucillamine as a potential treatment for severe cases of COVID-19 today, according to a press release. The research will be done by Dr. John Fahy with the intention of testing the efficacy of Bucillamine in pre-clinical models of…
-
![Cybin (CYBN.NE) demonstrates Proof of Concept on CYB003 and CYB004 psychedelic molecules]()
Cybin (CYBN.NE) demonstrates Proof of Concept on CYB003 and CYB004 psychedelic molecules
Cybin (CYBN.NE) announced that they have successfully demonstrated Proof of Concept for their deuterated tryptamine programs, CYB003 and CYB004. The Proof of Concept revolves around the duration of psilocybin. A normal psilocybin experience will last around six hours, and can take up to an hour to begin. However, in their press release, Cybin notes that…
-
![Revive Therapeutics (RVV.C) finds $23 million and throws it at their bucillamine clinical studies]()
Revive Therapeutics (RVV.C) finds $23 million and throws it at their bucillamine clinical studies
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically their recent $23 million financing. The company intends to use the monies to fund their aggressive expansion from14 clinical sites to 50 to meet their enrolment requires for the study…
-
![Algernon Pharmaceuticals (AGN.C) gets ethical green light for human trials for COVID-19 fighter Ifenprodil]()
Algernon Pharmaceuticals (AGN.C) gets ethical green light for human trials for COVID-19 fighter Ifenprodil
The scientific process isn’t exactly what you were taught in grade 4. There’s a lot more to it, owing to some historical—well, let’s call them what they are—atrocities, which have taken place as long as white lab-coats have been all the rage in knowledge-defining circles. This process is expensive in both time and money and…
-
What the FDA thinks of Curaleaf (CURA.C), the ‘world’s largest cannabis co.’
On July 22, 2019, the U.S. Food and Drug Administration (FDA) sent a warning letter to Curaleaf Holdings (CURA.C) via overnight delivery. The message was plain: Four of the company’s CBD-infused products are “in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act,” and Curaleaf’s CBD products for pets are “unapproved new…
